CeraVe to restore skin hydration as maintenance for mild-to-moderate atopic dermatitis
Official title: Analysis of the CeraVe Emollient Effect on Restoring the Hydration of the Skin Barrier as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis
Run by Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse · NCT07204561 · Data updated 2026-11-12
This trial will test whether using CeraVe moisturizing cream as a maintenance treatment keeps skin hydrated in adults with mild-to-moderate atopic dermatitis after steroid-induced clearance.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 98 (estimated) |
| Sponsor | Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse Academic / other |
| Locations | 1 site (Roma, RM) |
| Status | Recruiting |
| Started | March 25, 2025 |
| Main results expected | July 2026 |
| Study ends | July 2026 |
| Registry record updated | October 2, 2025 |
| Trial ID | NCT07204561 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with clinically confirmed mild-to-moderate atopic dermatitis who achieve ≥90% EASI reduction after steroid treatment and can give informed consent are eligible for randomization.
✕Probably not a fit
Patients using systemic AD therapies, those with other dermatologic conditions that confound assessment, or those who do not reach the required EASI improvement are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an open-label, randomized, comparative, prospective interventional trial comparing CeraVe moisturizing cream to a standard pharmacy-prepared emollient as a maintenance regimen. Adult participants with mild-to-moderate atopic dermatitis (EASI 1-21) who achieve at least a 90% EASI reduction after topical steroid treatment will be randomized to one of the two emollients and given a basic detergent for washing. The primary outcome is restoration of skin barrier hydration, with secondary endpoints including cosmetic acceptability and differences in ADCT scores. Participants will discontinue if they experience a documented relapse of atopic dermatitis.
Why it matters
Potential benefit: If successful, patients may get improved skin hydration and potentially longer maintenance of disease control using a widely available moisturizer.
How similar studies have gone: Regular emollient maintenance is a well-established approach with evidence of benefit, but direct randomized comparisons of CeraVe versus a pharmacy-made emollient are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: Subjects with clinically confirmed mild-to-moderate atopic dermatitis (AD), as defined by an Eczema Area and Severity Index (EASI) score of 1-21, whose lesions will clear after treatment with a steroid and who will experience at least a 90% reduction in their EASI score. \- Participants of any gender, aged 18 years or over, from any phototype or ethnic group. Participants must be willing and able to give informed consent to participate in the study. Exclusion criteria: * Age \<18 years. Participants who are unwilling or unable to give informed consent to participate in the study. * Receiving any systemic treatment for atopic dermatitis (AD), including corticosteroids, cyclosporine, any approved biologics or JAK inhibitors. * Any dermatological disorder which, in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics (except AD).
Where it's running
-
Fondazione PTV - Policlinico Tor Vergata
Roma, Rm, Italy Recruiting
Study contacts
- Study coordinator: Prof.ssa Elena Campione
- Email: elena.campione@ptvonline.it
- Phone: +39 0620908446
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults
A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.
-
LT-002-158 tablets for moderate-to-severe atopic dermatitis in adults
This study tests LT-002-158 vs placebo to see if it helps adults with moderate-to-severe atopic dermatitis.
-
PRA-216 for moderate to severe atopic dermatitis: safety and how it works in the body
This study tests PRA-216 versus placebo to see if it is safe and helps people with moderate to severe atopic dermatitis.
-
Skin structure in atopic dermatitis patients treated with nemolizumab assessed by reflectance confocal microscopy
This study tests whether nemolizumab changes skin structure in adults with moderate-to-severe atopic dermatitis using a noninvasive imaging method.
-
Global Health Look at Atopic Dermatitis
A worldwide, multicenter study tests how people with atopic dermatitis access care and treat it, using data from routine medical records.
-
Stapokibart Injection for atopic dermatitis in adults
This study tests Stapokibart Injection in adults with atopic dermatitis to see how safe it is and whether it helps.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.